Overview
Welcome to Immunicum's Investor Relations pages. Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact CEO Carlos de Sousa.
Carlos de Sousa, CEO
Phone: +46(0)8 732 8400
Email: info@immunicum.com
CEO statement, Q2 report 2019
“Having ended the second quarter on a positive note, it is clear 2019 remains a pivotal year for Immunicum. This year we will obtain valuable insights into the safety, efficacy and mechanism of action of our allogeneic, off-the-shelf, cell-based therapy, ilixadencel. As we advance into the second half of the year, we look forward to reaching additional milestones and to expanding our insights on ilixadencel. Most importantly, we are preparing for the announcement of the results from the global Phase II MERECA study in kidney cancer patients.”
To read the full report, please click here
Investor Downloads
